Evidence map›Paper›PMID 29419442›Full record

ArticleThe European respiratory journal2018

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Onno W Akkerman, Floris Grasmeijer, Wiel C M de Lange, Huib A M Kerstjens, Gerard de Vries, Mathieu S Bolhuis, Jan-Willem Alffenaar, Henderik W Frijlink, Grace Smith, Roger Gajraj and 5 more

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Clinical standards for drug-susceptible pulmonary TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
  2. Engineered drug delivery devices to address Global Health challenges.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  3. Review
  4. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.Antimicrobial resistance and infection control · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Onno W AkkermanUniversity of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands o.w.akkerman@umcg.nl.
Floris GrasmeijerUniversity of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands.
Wiel C M de LangeUniversity of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
Huib A M KerstjensUniversity of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
Gerard de VriesKNCV Tuberculosis Foundation, Den Haag, The Netherlands.
Mathieu S BolhuisUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Jan-Willem AlffenaarUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Henderik W FrijlinkUniversity of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands.
Grace SmithNational Mycobacteriology Reference Unit, Birmingham, UK.
Roger GajrajPublic Health England, Birmingham, UK.
Rina de ZwaanNational Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Paul HagedoornUniversity of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands.
Martin DedicoatDept of Infection, Heart of England Foundation Trust, Birmingham, UK.
Dick van SoolingenNational Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Tjip S van der WerfUniversity of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntitubercular AgentsColistinDiarylquinolinesDrug SynergismExtensively Drug-Resistant TuberculosisHumansIsoniazidMaleMedication AdherenceMycobacterium tuberculosisNetherlandsNitroimidazolesOxazolesPatient IsolationPhenotypeAntitubercular AgentsbedaquilineColistinDiarylquinolinesIsoniazidNitroimidazolesOPC-67683OxazolesTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID29419442
PMCPMC5863047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.